New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Check below for free stories on CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
08:32 EDTOXBTOxygen Biotherapeutics announces name change to Tenax Therapeutics
Subscribe for More Information
September 12, 2014
13:30 EDTSYNSynthetic Biologics confirms receipt of orphan drug designation for SYN-005
Subscribe for More Information
10:32 EDTAMBSAmarantus Bioscience completes enrollment of 72 patient LP-002 study
Subscribe for More Information
10:03 EDTSYNSynthetic Biologics treatment of Bordetella pertussis granted orphan status
Reference Link
09:14 EDTOXBTOn The Fly: Pre-market Movers
Subscribe for More Information
07:00 EDTSYNSynthetic Biologics to host investor day
Investor Day to be held on September 16 at 9 am. Webcast Link
September 11, 2014
17:32 EDTOXBTOxygen Biotherapeutics announces halt of Oxycyte Phase IIb trial
Subscribe for More Information
17:25 EDTOXBTOxygen Biotherapeutics trading halted, pending news
Subscribe for More Information
07:49 EDTSYNSynthetic Biologics to host conference call
Subscribe for More Information
September 10, 2014
07:09 EDTSYNAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 8, 2014
07:18 EDTAGENRodman & Renshaw to hold a conference
Subscribe for More Information
September 7, 2014
17:11 EDTSYNSynthetic Biologics highlights new data from C. difficile program
Synthetic Biologics announced preclinical data that further validate the company's novel approach to preventing Clostridium difficile,C. difficile. The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it has surpassed MRSA as the number one hospital-acquired infection in the United States. The data were highlighted on September 6 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, D.C.
September 5, 2014
11:52 EDTCANFCan-Fite receives Japanese patent for liver function treatment after surgery
Can-Fite BioPharma announced earlier the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent Office. The patent covers Can-Fite's clinical stage drug candidate, CF102, in the treatment of liver regeneration and function following liver surgery or other injury via inhibition of pro-apoptotic proteins, resulting in liver repair.
September 4, 2014
17:18 EDTHARTHarvard Apparatus granted orphan status for inBreath airway transplant system
Subscribe for More Information
September 2, 2014
08:32 EDTCGIXCancer Genetics IVD for cervical cancer receives CE Mark
Cancer Genetics announced that their proprietary DNA-probe based test for cervical cancer, or FHACT, has received the CE Marking. The CE marking indicates the test's compliance with European Union product safety legislation and allows FHACT to be sold freely within the European Economic Area, or EEA, which includes the 28 member states of the EU as well as the European Free Trade Association. Cancer Genetics' proprietary FHACT test, which can identify irreversible genomic changes associated with progression to cancer, adds predictive value to this screening protocol. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
07:36 EDTSYNSynthetic Biologics announces positive results from study of SYN-004
Subscribe for More Information
07:07 EDTCANFCan-Fite BioPharma reports H1 EPS (NIS71c) vs. last year (NIS1.11)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use